HeartWare Records Another Rough Quarter; Looks To ENDURANCE 2 Trial For Turn-Around
This article was originally published in Clinica
Executive Summary
HeartWare is counting on the ENDURANCE II trial to earn the coveted destination therapy indication for its HVAD ventricular assist device, and help pull its sales and earnings out its current slump.